Logo image of VANI

VIVANI MEDICAL INC (VANI) Stock Price, Forecast & Analysis

USA - Nasdaq - NASDAQ:VANI - US92854B1098 - Common Stock

1.23 USD
0 (0%)
Last: 12/31/2025, 8:00:02 PM
1.2482 USD
+0.02 (+1.48%)
After Hours: 12/31/2025, 8:00:02 PM

VANI Key Statistics, Chart & Performance

Key Statistics
Market Cap89.73M
Revenue(TTM)N/A
Net Income(TTM)-26.03M
Shares72.95M
Float43.90M
52 Week High1.92
52 Week Low0.91
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.45
PEN/A
Fwd PEN/A
Earnings (Next)03-30 2026-03-30
IPO2014-12-05
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment


VANI short term performance overview.The bars show the price performance of VANI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -2 -4 -6 -8 -10

VANI long term performance overview.The bars show the price performance of VANI in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 20 30 40

The current stock price of VANI is 1.23 USD. In the past month the price decreased by -8.21%. In the past year, price decreased by -3.91%.

VIVANI MEDICAL INC / VANI Daily stock chart

VANI Competitors/Peers

The largest stocks on the US markets in the "Health Care Equipment" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABT ABBOTT LABORATORIES 25.11 217.86B
ISRG INTUITIVE SURGICAL INC 65.78 200.77B
BSX BOSTON SCIENTIFIC CORP 32.32 141.35B
SYK STRYKER CORP 26.69 134.41B
BDX BECTON DICKINSON AND CO 13.46 55.39B
IDXX IDEXX LABORATORIES INC 53.65 54.02B
EW EDWARDS LIFESCIENCES CORP 33.17 49.47B
GEHC GE HEALTHCARE TECHNOLOGY 17.87 37.36B
RMD RESMED INC 24.33 35.16B
DXCM DEXCOM INC 35.68 25.89B
PODD INSULET CORP 62.2 20.00B
ZBH ZIMMER BIOMET HOLDINGS INC 11.11 17.82B

About VANI

Company Profile

VANI logo image Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.

Company Info

VIVANI MEDICAL INC

1350 S. Loop Road

Alameda CALIFORNIA US

Employees: 42

VANI Company Website

VANI Investor Relations

Phone: 14155068462

VIVANI MEDICAL INC / VANI FAQ

Can you describe the business of VIVANI MEDICAL INC?

Vivani Medical, Inc. is a preclinical stage biopharmaceutical company, which engages in the business of developing miniaturized, subdermal implants utilizing proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases. The company is headquartered in Alameda, California and currently employs 42 full-time employees. The company went IPO on 2014-12-05. Leveraging its NanoPortal platform, it develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence, and to improve patient tolerance to their medication. Its lead program, NPM-115, is a six-month, subdermal, GLP-1 (exenatide) implant under development for chronic weight management in overweight individuals. Its pipeline includes NPM-139 (semaglutide implant), which is also under development for chronic weight management. NPM-119 refers to its six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the benefit of their medication by avoiding the challenges associated with the daily or weekly administration of orals and injectables.


What is the current price of VANI stock?

The current stock price of VANI is 1.23 USD.


What is the dividend status of VIVANI MEDICAL INC?

VANI does not pay a dividend.


What is the ChartMill technical and fundamental rating of VANI stock?

VANI has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Can you provide the sector and industry classification for VIVANI MEDICAL INC?

VIVANI MEDICAL INC (VANI) operates in the Health Care sector and the Health Care Equipment & Supplies industry.


How many employees does VIVANI MEDICAL INC have?

VIVANI MEDICAL INC (VANI) currently has 42 employees.


What is the market capitalization of VANI stock?

VIVANI MEDICAL INC (VANI) has a market capitalization of 89.73M USD. This makes VANI a Micro Cap stock.


VANI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

VANI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to VANI. While VANI seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VANI Financial Highlights

Over the last trailing twelve months VANI reported a non-GAAP Earnings per Share(EPS) of -0.45. The EPS decreased by 0% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -103.91%
ROE -1988.24%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)0%
Revenue 1Y (TTM)N/A

VANI Forecast & Estimates

8 analysts have analysed VANI and the average price target is 5.1 USD. This implies a price increase of 314.63% is expected in the next year compared to the current price of 1.23.


Analysts
Analysts82.5
Price Target5.1 (314.63%)
EPS Next Y2.64%
Revenue Next YearN/A

VANI Ownership

Ownership
Inst Owners5.37%
Ins Owners45.58%
Short Float %0.5%
Short Ratio0.65